BridgeBio Pharma (BBIO) Cash from Operations (2018 - 2026)
BridgeBio Pharma (BBIO) posted Cash from Operations of 197279000.0 for Q1 2026, down 249.66% sequentially from 56420000.0 in Q4 2025, and up 0.98% YoY from 195361032.87 in Q1 2025.
BridgeBio Pharma (BBIO) Cash from Operations (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Cash from Operations for 9 years, with the latest figure at 197279000.0 in Q1 2026.
- Quarterly Cash from Operations rose 0.98% year-over-year to 197279000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 443954000.0 (up 11.28% YoY) and the FY2025 annual result came in at 445910000.0, up 14.37% from the prior year.
- Cash from Operations eased to 197279000.0 in Q1 2026 per BBIO's latest filing, from 56420000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 74703000.0 in Q2 2024 and troughed at 219537000.0 in Q1 2024.
- A 5-year average of 124184058.82 and a median of 135163000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations plunged 272.22% in 2023, then soared 165.9% in 2024.
- Over 5 years, Cash from Operations stood at 93243000.0 in 2022, then slumped by 33.86% to 124819000.0 in 2023, then plunged by 56.49% to 195326000.0 in 2024, then soared by 71.11% to 56420000.0 in 2025, then tumbled by 249.66% to 197279000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 197279000.0, 56420000.0, and 109574000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | -71.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -71.10 Mn |
| Jun 30, 2026 | -71.10 Mn |
| Mar 31, 2026 | -197.28 Mn |
| Mar 31, 2026 | -197.28 Mn |
| Dec 31, 2025 | -56.42 Mn |
| Dec 31, 2025 | -56.42 Mn |
| Sep 30, 2025 | -109.57 Mn |
| Sep 30, 2025 | -109.57 Mn |
| Jun 30, 2025 | -80.68 Mn |
| Jun 30, 2025 | -80.68 Mn |
| Mar 31, 2025 | -199.24 Mn |
| Mar 31, 2025 | -199.24 Mn |
| Dec 31, 2024 | -195.33 Mn |
| Dec 31, 2024 | -195.33 Mn |
| Sep 30, 2024 | -180.57 Mn |
| Sep 30, 2024 | -180.57 Mn |
| Jun 30, 2024 | 74.70 Mn |
| Jun 30, 2024 | 74.70 Mn |
| Mar 31, 2024 | -219.54 Mn |
| Mar 31, 2024 | -219.54 Mn |